Granules India shares climb nearly 7% on USFDA nod for drug
The scrip advanced by 6.61% to end at Rs103.15 on BSE. Intra-day, it zoomed 10.18% to Rs106.60. On NSE, shares of the company surged 6.67% to close at Rs103.15
New Delhi:Shares of drug firm Granules India Thursday soared nearly 7% after the company’s subsidiary received approval from the US health regulator for Methylergonovine tablets, used for prevention and control of postpartum haemorrhage.
The scrip advanced by 6.61% to end at Rs103.15 on BSE. Intra-day, it zoomed 10.18% to Rs106.60. On NSE, shares of the company surged 6.67% to close at Rs103.15.
On the equity volume front, 8.75 lakh shares of the company were traded on BSE and over one crore shares changed hands on NSE during the day.
In a filing to the BSE, Granules India said, “the US Food and Drug Administration (US FDA) has approved its abbreviated new drug applications (ANDA) for Methylergonovine 0.2 mg tablets.
The ANDA was filed by Granules Pharmaceuticals Inc, a wholly owned subsidiary of Granules India Ltd”.
- Will RBI’s sops ease the liquidity crunch at NBFCs?
- Paytm launches PayPay in Japan, in joint venture with SoftBank, Yahoo Japan
- Cash-strapped IL&FS wants government to bail it out
- Flipkart’s Sachin Bansal and Ola’s Bhavish Aggarwal: Cut from the same cloth
- Cube Wealth raises ₹14 crore in Series A funding
Editor's Picks »
- Reliance Jio seen overtaking Vodafone Idea, Airtel to become India’s largest telecom firm by 2018-end
- ArcelorMittal’s Essar Steel acquisition: Who wins, who loses
- UltraTech’s dismal Q2 results darken outlook on cement sector
- NBFC liquidity crisis set to worsen real estate sector woes
- RBI pause on interest rate hike may last only till December